Low-Carb Diet's Impact on Semaglutide Weight Loss Explored in Pilot Trial

The injectable GLP-1 agonist Semaglutide has demonstrated significant efficacy for weight loss and improving glycemic control in individuals with obesity or type 2 diabetes. However, the optimal dietary strategy to maximize these benefits and enhance metabolic outcomes when combined with semaglutide remains an area of active research. This pilot trial aims to determine if a low-carbohydrate, higher-protein diet can further improve weight loss, body composition, and cardiovascular risk markers compared to a standard low-fat diet in semaglutide users.